Tsiligiannis S, Panay N, Stevenson JC. Premature ovarian insufficiency and long-term health consequences. Curr Vasc Pharmacol 2019; 17: 604-9.
Stevenson JC, Tsiligiannis S, Panay N. Cardiovascular risk in perimenopausal women. Curr Vasc Pharmacol 2019; 17: 591-94.
Mumusoglu S, Yildiz BO. Metabolic syndrome during menopause. Curr Vasc Pharmacol 2019; 17: 595-603.
Paschou SA, Anagnostis P, Pavlou DI, Vryonidou A, Goulis DG, Lambrinoudaki I. Diabetes in menopause: Risks and management. Curr Vasc Pharmacol 2019; 17: 556-63.
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 3975-4011.
Cobin RH, Goodman NF. American association of clinical endocrinologists and American college of endocrinology position statement on menopause-2017 update. Endocr Pract 2017; 23: 869-80.
Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
Anagnostis P, Paschou SA, Katsiki N, Krikidis D, Lambrinoudaki I, Goulis DG. Menopausal hormone therapy and cardiovascular risk. Where are we now? Curr Vasc Pharmacol 2019; 17: 564-72.
Mareti E, Ampatzi C, Paschou SA, Voziki E, Goulis DG. Non-hormonal replacement therapy regimens: Do they have an effect on cardiovascular risk? Curr Vasc Pharmacol 2019; 17: 573-8.
Lambrinoudaki I, Armeni E. Cardiovascular risk in postmenopausal women with polycystic ovary syndrome. Curr Vasc Pharmacol 2019; 17: 579-90.
Venetsanaki V, Polyzos SA. Menopause and non-alcoholic fatty liver disease: A review focusing on therapeutic perspectives. Curr Vasc Pharmacol 2019; 17: 546-55.
Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism 2018; 86: 33-43.
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
Muscogiuri G, Barrea L, Altieri B, et al. Calcium and vitamin D supplementation in musculoskeletal health: What about cardiovascular risk? Curr Vasc Pharmacol 2019; 17: 610-7.
Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of gender, age and menopausal status on serum apolipoprotein concentrations. Clin Endocrinol (Oxf) 2016; 85: 733-40.
Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas 2015; 81: 62-8.
Cho GJ, Lee JH, Park HT, et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause 2008; 15: 524-9.
Azizi F, Ainy E. Coronary heart disease risk factors and menopause: A study in 1980 Tehranian women, the Tehran Lipid and Glucose Study. Climacteric 2003; 6: 330-6.
Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123-33.
Maas AH, Franke HR. Women’s health in menopause with a focus on hypertension. Neth Heart J 2009; 17: 68-72.
Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: A meta-analysis. Climacteric 2016; 19: 27-36.
Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 178-86.
Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: A systematic review and meta-analysis. JAMA Cardiol 2016; 1: 767-76.
Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: A systematic review and meta-analysis. Eur J Endocrinol 2019; 180: 41-50.